Use of multiple biological markers in radiotherapy-treated head and neck cancer

2010 ◽  
Vol 124 (6) ◽  
pp. 650-658 ◽  
Author(s):  
P Silva ◽  
N J Slevin ◽  
P Sloan ◽  
H Valentine ◽  
D Ryder ◽  
...  
Keyword(s):  
Squamous Cell Carcinoma ◽  
Carbonic Anhydrase ◽  
Cell Carcinoma ◽  
Head And Neck ◽  
Squamous Cell ◽  
Biological Markers ◽  
Biological Marker ◽  
Locoregional Control ◽  
Major Vault Protein ◽  
Carbonic Anhydrase 9

AbstractObjective:Management of patients with head and neck squamous cell carcinoma is often based on clinical parameters, with little appreciation of the underlying tumour biology. Single biological marker studies fail to acknowledge the complexity of these tumours. Our aim was to define a profile of biological markers associated with outcome.Design:This retrospective study involved consecutive patients with oropharyngeal squamous cell carcinoma treated with primary radiotherapy between 1996 and 2001. Pre-treatment biopsies were used to study the immunohistochemical expression of nine biological markers. Markers were chosen to reflect biologically relevant pathways.Results:Following analysis of nine markers, a profile of two markers was derived (carbonic anhydrase 9 and major vault protein), the co-expression of which conferred a significantly poor probability of locoregional control. The prognostic effect of these biomarkers in combination was greater than their effect individually.Conclusion:Biomarker profiles can be established which highlight large differences in locoregional control. Identifying tumours that express both carbonic anhydrase 9 and major vault protein may facilitate patient selection for more aggressive treatment.

scholarly journals High Survival and Organ Function Rates After Primary Chemoradiotherapy for Intermediate-Stage Squamous Cell Carcinoma of the Head and Neck Treated in a Multicenter Phase II Trial

2006 ◽  
Vol 24 (21) ◽  
pp. 3438-3444 ◽  
Author(s):  
Ezra E.W. Cohen ◽  
Daniel J. Haraf ◽  
Marcy A. List ◽  
Masha Kocherginsky ◽  
Bharat B. Mittal ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Squamous Cell Carcinoma ◽  
Cell Carcinoma ◽  
Head And Neck ◽  
Squamous Cell ◽  
Patient Population ◽  
Intermediate Stage ◽  
Locoregional Control ◽  
Primary Tumor Site

Purpose Patients with intermediate-stage squamous cell carcinoma of the head and neck traditionally have been treated with initial surgical resection followed by radiotherapy (RT) alone or chemoradiotherapy. A previous study in this patient population reported a 91% locoregional control rate and 65% overall survival (OS) rate at 5 years, with chemoradiotherapy used as primary treatment. This study was undertaken to assess whether shortening treatment duration with hyperfractionated RT would be feasible and improve locoregional control, organ preservation, and progression-free survival. Methods Eligible patients with stage II or III disease received fluorouracil, hydroxyurea, and RT given twice daily on a week-on/week-off schedule. Quality-of-life scores were measured using three validated indexes. Results All 53 patients enrolled are included in the analysis, with a median follow-up of 42 months (range, 5 to 98 months). Grade 3 or 4 in-field mucositis was observed in 77% and 9%, respectively. No patients required surgical salvage at the primary tumor site (pathological complete response rate, 100%). The 3-year progression-free and OS rates are 67% and 78%, respectively. The 3-year disease-specific mortality rate is 7%. At the time of analysis, 87% of surviving patients do not require enteral feeding support. Quality-of-life and performance assessment indicated that, although acute treatment toxicities were severe, most patients returned to pretreatment function by 12 months. Conclusion Concurrent chemoradiotherapy with hyperfractionated RT is feasible in this patient population and yields high local control and cure rates. Compared with our historical control using once-daily fractionation, hyperfractionation is accompanied by increased acute in-field toxicity.

Does systemic treatment add value to stereotactic body radiation therapy for locoregional control in head and neck squamous cell carcinoma patients?

2019 ◽  
Vol 37 (15_suppl) ◽  
pp. e17505-e17505
Author(s):  
Andrea M Tufano ◽  
James Newman ◽  
Emile Gogineni ◽  
Jessie L Karten ◽  
Doru Paul ◽  
...  
Keyword(s):  
Squamous Cell Carcinoma ◽  
Disease Control ◽  
Cell Carcinoma ◽  
Head And Neck ◽  
Squamous Cell ◽  
Systemic Treatment ◽  
Neck Squamous Cell Carcinoma ◽  
Locoregional Control ◽  
Secondary Outcome ◽  
Poor Performance Status

e17505 Background: Stereotactic body radiotherapy (SBRT) has been shown to provide locoregional control in head and neck squamous cell carcinoma (HNSCC) patients (pts) who are not candidates for curative procedures due to poor performance status, comorbidities, or radiation dose limitations from prior treatment. The addition of chemotherapy (chemo) and/or cetuximab (CET) is hypothesized to improve outcomes compared to SBRT alone, but there is limited data on comparative effectiveness. We compared outcomes of pts treated with SBRT vs. SBRT + chemo and/or CET using retrospective observational data from our institution. Methods: We identified new and recurrent HNSCC pts treated with SBRT +/- systemic therapy from 2012 to 2018. Age, Charlson Comorbidity Index (CCI) and stage were recorded. Primary outcome was locoregional disease control rate based on Modified Response Evaluation Criteria in Solid Tumors on 3-month post-treatment imaging. Secondary outcome was overall survival (OS) at 1 year. Pts were divided into 4 groups: SBRT, SBRT+chemo, SBRT+CET, and SBRT+chemo+CET (cohorts A, B, C and D, respectively). Results: 90 pts with median age of 73 years and median follow-up of 11.5 months were included. 94.4% were stage III or IV, and 68.9% had recurrent disease. The most commonly utilized chemotherapy was carboplatin and paclitaxel. Cohorts A, B, C and D constituted 28.9%, 31.1%, 31.1% and 8.8% respectively. Groups were well matched except for pts in Cohort A being significantly older than those in Cohort B (74.9 vs. 68.4 years; p = 0.01). Average CCI estimated 10-year survival was 8.4%. There was a trend towards improved locoregional control at 3 months in Cohort B vs. A (57.1% vs. 34.6%, p = 0.09), and improved OS at 1 year (46.4% vs. 23.1%; p = 0.07). These trends were not observed in comparisons between other cohorts. Conclusions: Chemo + SBRT may improve disease control as well as 1 year OS in HNSCC pts who do not qualify for curative procedures. Given the younger age of pts receiving chemo, selection bias cannot be excluded. Prospective studies with larger patient cohorts are needed to further evaluate the benefits and toxicities of adding systemic treatment to SBRT in this population.

scholarly journals ADH7 Polymorphism and Alcohol Consumption on Risk of Head and Neck Squamous Cell Carcinoma in The Korean Population

2021 ◽  
Author(s):  
Dong Won Lee ◽  
Yong Bae Ji ◽  
Chang Myeon Song ◽  
Jeong Kyu Kim ◽  
Seung Hwan Lee ◽  
...  
Keyword(s):  
Squamous Cell Carcinoma ◽  
Alcohol Consumption ◽  
Cell Carcinoma ◽  
Head And Neck ◽  
Squamous Cell ◽  
Biological Marker ◽  
Risk Groups ◽  
Neck Squamous Cell Carcinoma ◽  
Taqman Assay ◽  
Synergistic Interactions

Abstract Purpose The development of head and neck squamous cell carcinoma (HNSCC) is closely associated with alcohol consumption. Also, it is related to individual genetic susceptibility, such as single nucleotide polymorphism (SNP) of alcohol dehydrogenase (ADH). This study aimed to investigate the association of ADH7 SNPs with the risk of HNSCC. Methods and Patients: We analyzed ADH7 rs1573496C > G, rs3737482T > C, rs1154460G > A, and rs284787T > C SNPs in 250 patients with HNSCC and 322 controls in the Korean populations. Genomic DNA was extracted from peripheral blood, and genotyping was done using the TaqMan assay. Linkage disequilibrium (LD) and haplotypes were analyzed. Results The odds ratios (OR) and 95% confidence intervals (CI) of the CT and CC genotypes of ADH7 rs3737482T > C were 0.48 (0.29–0.78) and 0.69 (0.49–0.96), indicating a significantly decreased risk. In SNP of rs1154460G > A, the OR and 95% CI of the AA genotype was 1.63 (1.11–2.40), showing a significant increase in the risk. Furthermore, SNPs of ADH7 rs3737482T > C and ADH7 rs1154460G > A exhibit synergistic interactions with alcohol composition on the risk of HNSCC. None of the haplotypes were associated with the risk of HNSCC. Conclusions ADH7 rs3737482T > C and rs1154460G > A SNPs are associated with the risk of development of HNSCC in Koreans. It could serve as a molecular biological marker to screen the high-risk groups for HNSCC.

scholarly journals Association between Carbonic anhydrase 9 expression and poor prognosis in sinonasal squamous cell carcinoma

2020 ◽  
Author(s):  
Lan Lin ◽  
Chunyan Hu ◽  
Huan Wang ◽  
Xicai Sun ◽  
Dehui Wang
Keyword(s):  
Squamous Cell Carcinoma ◽  
Carbonic Anhydrase ◽  
Cell Carcinoma ◽  
Squamous Cell ◽  
Poor Prognosis ◽  
Disease Free Survival ◽  
Curative Surgery ◽  
Positive Expression ◽  
Negative Prognostic Factor ◽  
Carbonic Anhydrase 9

Abstract Background: Carbonic anhydrase 9(CA9), as a member of the carbonic anhydrase enzyme family, was an endogenous marker of hypoxia. Previous studies suggested CA9 expression was correlated with poor prognosis in multiple types of malignancies. The purpose of current study was to evaluate the role of CA9 as a prognostic marker in sinonasal squamous cell carcinoma(SNSCC).Patients and methods: We assessed the immunohistochemical expression of CA9 in 63 tumor specimens of patients who underwent curative surgery and evaluated the relationship between the expression levels and clinicopathological factors as well as outcome.Results: We observed positive expression of CA9 in 21(33.3%) patients. Positive expression of CA9 in patients with SNSCC was significantly correlated with local recurrence (p=0.016) and both overall survival (OS) (p=0.003) and disease-free survival (DFS) (p=0.002). In Cox's multivariate analysis, CA9 expression was an independent negative prognostic factor for OS (p=0.027) and DFS (p=0.018).Conclusions: Our findings demonstrated that CA9 overexpression could be used as an independent prognostic biomarker and therapeutic target in SNSCC.

scholarly journals Association of Body Composition With Survival and Locoregional Control of Radiotherapy-Treated Head and Neck Squamous Cell Carcinoma

JAMA Oncology ◽  
2016 ◽  
Vol 2 (6) ◽  
pp. 782 ◽  
Author(s):  
Aaron J. Grossberg ◽  
Sasikarn Chamchod ◽  
Clifton D. Fuller ◽  
Abdallah S. R. Mohamed ◽  
Jolien Heukelom ◽  
...  
Keyword(s):  
Squamous Cell Carcinoma ◽  
Body Composition ◽  
Cell Carcinoma ◽  
Head And Neck ◽  
Squamous Cell ◽  
Neck Squamous Cell Carcinoma ◽  
Locoregional Control
Sign in / Sign up

Export Citation Format

Share Document